XML 53 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Customers and Concentration of Credit Risk (Notes)
 9 Months Ended
Sep. 30, 2014
Risks and Uncertainties [Abstract]  
Significant Customer and Concentration of Credit Risk
Significant Customers and Concentration of Credit Risk

The company is engaged in the business of developing and commercializing pharmaceutical products. As of September 30, 2014, the company had one active commercial product, Abstral, available in six dosing strengths, and all sales reported are in the United States.

Sales to the following customers represented 10% or more of net revenue during at least one of the periods are presented as follows:

 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Customer
 
2014
 
2013
 
2014
 
2013
Customer A
 
40
%
 
8
%
 
44
%
 
8
%
Customer B
 
—
%
 
64
%
 
16
%
 
64
%
Customer C
 
27
%
 
17
%
 
14
%
 
17
%
Customer D
 
11
%
 
—
%
 
5
%
 
—
%
Customer E
 
14
%
 
6
%
 
10
%
 
6
%

The following customers represented 10% or more of total accounts receivable as of at least one of the balance sheet dates presented:

 
 
September 30, 2014
 
December 31, 2013
Customer
 
(Unaudited)
 
Customer A
 
39
%
 
25
%
Customer B
 
8
%
 
11
%
Customer C
 
25
%
 
1
%
Customer D
 
10
%
 
—
%
Customer E
 
12
%
 
54
%

Our gross revenue is affected by the timing of customer orders, which timing sometimes results in quarter-to-quarter fluctuations in gross revenue. From time to time we have offered favorable pricing and extended payment terms to new wholesale distributor customers as an incentive to place initial Abstral orders. In the second quarter of 2014, we afforded such incentives to one of our principal customers with respect to an order from which we recognized approximately $1.5 million of gross revenue (ex-manufacturer), or approximately $0.9 million of net revenue.